A single arm, multi-center Phase 2 trial of mFOLFOX6 + trastuzumab + avelumab in first-line, metastatic, HER2-amplified gastric and esophageal adenocarcinoma

Learn more:

• clinicaltrials.gov: #NCT03783936
• News release

Abstracts/Posters/Presentations:

• MS Lee, J Chao, MF Mulcahy, PM Kasi, AT Alistar, S Mukherjee, M Akce, DT Moore, CA Carlson, AJ McRee. Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma. Presented as a poster at the American Association for Cancer Research (AACR) 2021 Annual Meeting. See abstract.